"Protein-Tyrosine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.
| Descriptor ID |
D011505
|
| MeSH Number(s) |
D08.811.913.696.620.682.725
|
| Concept/Terms |
Protein-Tyrosine Kinases- Protein-Tyrosine Kinases
- Kinases, Protein-Tyrosine
- Protein Tyrosine Kinases
- Tyrosine Kinase
- Kinase, Tyrosine
- Tyrosine Protein Kinase
- Kinase, Tyrosine Protein
- Tyrosylprotein Kinase
- Kinase, Tyrosylprotein
- Tyrosine-Specific Protein Kinase
- Kinase, Tyrosine-Specific Protein
- Protein Kinase, Tyrosine-Specific
- Tyrosine Specific Protein Kinase
- Tyrosine-Specific Protein Kinases
- Kinases, Tyrosine-Specific Protein
- Protein Kinases, Tyrosine-Specific
- Tyrosine Specific Protein Kinases
- Protein-Tyrosine Kinase
- Kinase, Protein-Tyrosine
- Protein Tyrosine Kinase
- Tyrosine Protein Kinases
- Kinases, Tyrosine Protein
- Protein Kinases, Tyrosine
|
Below are MeSH descriptors whose meaning is more general than "Protein-Tyrosine Kinases".
Below are MeSH descriptors whose meaning is more specific than "Protein-Tyrosine Kinases".
This graph shows the total number of publications written about "Protein-Tyrosine Kinases" by people in this website by year, and whether "Protein-Tyrosine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 14 | 4 | 18 |
| 1995 | 15 | 13 | 28 |
| 1996 | 16 | 8 | 24 |
| 1997 | 13 | 11 | 24 |
| 1998 | 15 | 8 | 23 |
| 1999 | 15 | 10 | 25 |
| 2000 | 10 | 11 | 21 |
| 2001 | 24 | 9 | 33 |
| 2002 | 20 | 24 | 44 |
| 2003 | 19 | 32 | 51 |
| 2004 | 17 | 31 | 48 |
| 2005 | 31 | 23 | 54 |
| 2006 | 26 | 23 | 49 |
| 2007 | 20 | 23 | 43 |
| 2008 | 20 | 11 | 31 |
| 2009 | 15 | 18 | 33 |
| 2010 | 25 | 13 | 38 |
| 2011 | 29 | 19 | 48 |
| 2012 | 22 | 15 | 37 |
| 2013 | 21 | 11 | 32 |
| 2014 | 17 | 5 | 22 |
| 2015 | 24 | 13 | 37 |
| 2016 | 13 | 12 | 25 |
| 2017 | 12 | 16 | 28 |
| 2018 | 6 | 4 | 10 |
| 2019 | 7 | 5 | 12 |
| 2020 | 6 | 8 | 14 |
| 2021 | 10 | 6 | 16 |
| 2022 | 0 | 6 | 6 |
| 2023 | 3 | 8 | 11 |
| 2024 | 1 | 5 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein-Tyrosine Kinases" by people in Profiles.
-
Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer. Cancer Res. 2024 Nov 15; 84(22):3864-3880.
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
-
The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases. Leuk Lymphoma. 2024 Nov; 65(11):1659-1674.
-
The intrinsic substrate specificity of the human tyrosine kinome. Nature. 2024 May; 629(8014):1174-1181.
-
2021 WHO Classification of Lung Cancer: Molecular Biology Research and Radiologic-Pathologic Correlation. Radiographics. 2024 03; 44(3):e230136.
-
Unveiling promising breast cancer biomarkers: an integrative approach combining bioinformatics analysis and experimental verification. BMC Cancer. 2024 Jan 31; 24(1):155.
-
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer. JAMA Netw Open. 2023 12 01; 6(12):e2347700.
-
Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Cancer J. 2023 10 12; 13(1):156.
-
Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in?situ hybridization. Cancer Cytopathol. 2024 Jan; 132(1):41-49.
-
Localized upper extremity edema secondary to Bruton's tyrosine kinase inhibition. Leuk Lymphoma. 2023 12; 64(12):2047-2050.